Hi, I’m Graham Lindman, and I’d like to show you the most rebellious trade I’ve ever placed.
It was February 1st last year.
Nvidia was trading at $620… Every trading manual and "expert" would have told you, you needed the stock to move at least 5% to make real money.
But I didn’t care, I issued an alert on an option contract for $1.20.
Not $120… Not $12.
One dollar and twenty cents.
Eight days later? That trade paid out 108%... While NVDA barely budged 3%.
While there were some smaller gains and some that did not work out, here’s what I realized…
Everything they teach about options is wrong.
The truth? You don’t need big price moves, fancy strategies, or even huge accounts
Here’s what I’ve found: there’s an underground method that lets you…
Trade popular stocks like Apple, Google, and Nvidia for less than a Starbucks latte… Target 100%+ gains weekly, and profit when everyone else is stuck watching paint dry.
The secret? A market anomaly so counterintuitive, even seasoned traders don’t believe it until they see it work.
Like Ben from Ohio, who texted me:
Or Jim…
Now here’s why this matters today…
Even though we’re climbing now, things could fall apart any moment, like in 2008, as this chart shows you.
And this setup is going to be my edge as we approach the rest of the year, no matter what happens.
While I cannot promise future returns or against losses…
If you want to see how these dirt-cheap options work and get your hands on the next couple of trade setups…
I’ve detailed everything I’ve learned over the past 18 months of doing this right here.
By clicking the link above you agree to periodic updates from ProsperityPub and its partners (privacy policy)
A Fresh IPO That Long-Term Investors Shouldn't Ignore
Author: Jordan Chussler. Posted: 1/14/2026.
Quick Look
- While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential.
Of course, IPOs also carry substantial downside risk. But even conservative investors may find that some recently public companies deserve a place in buy-and-hold portfolios.
NEW LAW: Congress Approves Setup For Digital Dollar? (Ad)
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0
But according to Rep. Marjorie Taylor Green, it's a bill that contains "the entire setup, groundwork and infrastructure to move from cash to digital currency."
That may be true for one biotechnology company in the healthcare sector that recently went public.
Last Year's IPO Success Stories
Last year is a good example of why new listings shouldn't be dismissed by investors with lower risk tolerances.
AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have capitalized on its nearly 359% gain before it reached 30 days on the Nasdaq, but longer-term holders are also enjoying strong returns.
Others, such as Medline (NASDAQ: MDLN), disprove the notion that all IPOs are high-risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and now has a market cap above $55 billion.
Similarly, Smithfield Foods (NASDAQ: SFD)—known for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors.
Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, began trading on Jan. 9 and is hoping for a similar outcome in 2026 and beyond.
Why Are Radiopharmaceuticals Important?
Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of diseases including cancer, heart disease and neurological conditions.
Radiopharmaceuticals combine radioactive isotopes with a targeting molecule that seeks specific cells (for example, cancer cells) to deliver localized radiation doses, minimizing damage to healthy tissue compared with conventional radiation treatments.
According to industry consultancy Grand View Research, the global nuclear medicine market was estimated at nearly $18 billion in 2024 and is forecast to reach nearly $35 billion by 2030, a compound annual growth rate of about 10.16%.
Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant market—an important point for Boston-based Aktis Oncology.
Aktis Oncology's Clinical-Stage Biotech
Wall Street is expecting biotech IPOs to rebound in 2026 after funding cuts by the Trump administration notably slowed healthcare listings in 2025.
Aktis, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and produced one of the larger recent raises in the sector. The company secured $318 million in IPO proceeds and now carries a market cap of about $3.34 billion.
According to the company's prospectus, Aktis' executive team includes experts in drug development, approval and commercialization, and members of management have participated in bringing 14 currently FDA-approved products to market.
Aktis develops targeted alpha radiopharmaceuticals—a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue.
Aktis Oncology's Eli Lilly Connection
The firm is clinical-stage and pre-revenue, but that did not prevent it from attracting the attention of Eli Lilly (NYSE: LLY).
According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares to anchor the IPO. This builds on a 2024 collaboration between the companies to develop tumor-targeting radiopharmaceuticals, under which Lilly committed $60 million in cash and made an equity investment in Aktis, with potential milestone payments that could exceed $1 billion.
The significance of Eli Lilly's backing is notable. With a market cap of about $1.01 trillion, Lilly is the largest Big Pharma company by market value, and its net income rose nearly 109% year over year from 2023 to 2024. That momentum may continue when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5.
Between its equity stake and the recent $100 million in AKTS shares purchased, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
This email content is a sponsored email from ProsperityPub, a third-party advertiser of The Early Bird and MarketBeat.
The profits and performance shown are not typical to any one subscriber. We develop tools and strategies to the best of our ability, but no one can guarantee the future. There is always a risk of loss when trading past performance is not indicative of future results, and you may lose money. From 10/05/23-07/30/25 the average return per trade winners and losers was 32% with an average winner of 92% and a 66% win rate over a four day hold time.
If you need help with your account, please don't hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl. #620, Sioux Falls, SD 57103. U.S.A..
0 Response to "I broke every options “rule” with this trade"
Post a Comment